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Nervous System Degeneration Produced by
Acrylamide Monomer
by Peter S. Spencer* and Herbert H. Schaumburg*
Acrylamide, widely employed as a vinyl monomer in the polymer industry, is a potent
neurotoxin to man and to animals. The cumulative effect of prolonged, low-level exposure
to acrylamide monomer is the insidious development of a progressive peripheral
neuropathy. Sensory symptoms begin in the hands and feet (numbness, pins and
needles), certain reflexes are lost and, with severe exposure, muscle weakness and
atrophy occur in the extremities. The peripheral neuropathy may be supplemented by
symptoms indicative of central nervous system damage (ataxia, tremor, somnolence
and mental changes).
The neuropathologic basis for this clinical picture has been determined in cats.
Here, chronic acrylamide intoxication produces selective peripheral and central nerve
fiber degeneration. Degeneration first occurs in the extremities of long and large
nerve fibers which later undergo a progressive, seriate proximal axonal degeneration
known as dying-back. Especially vulnerable are sensory axons supplying Pacinian cor-
puscles and muscle spindles in the hindfoot toepads, while adjacent motor nerve axons
die back later. Distal central nerve fiber degeneration is seen in the medulla and
the cerebellum.
The neurotoxic property of acrylamide is of practical concern in two areas. One
major problem is the protection of factory workers engaged in the manufacture of
acrylamide. A sensitive test of neurologic function in these individuals, i.e., touch
sensation, based on the experimental observation of the exquisite vulnerability of
Pacinian corpuscles in acrylamide intoxicated cats, is presently under consideration.
The second area for concern is the exposure of the populace to minute amounts of
neurotoxic acrylamide monomer which contaminate acrylamide polymers currently
deployed in the environment. Federal restrictions on the maximum permitted exposure
to acrylamide, based on a largely clinical study of acrylamide neurotoxicity conducted
ten years ago, may require a re-evaluation in the light of recent advances which have
pinpointed the initial sites of nerve fiber degeneration.
Monomeric acrylamide (CH,CHCOCH2) is a
potent neurotoxin capable of producing nervous
system degeneration in a wide variety of ani-
mals (1-8). This property was first recognized
in the early 1950's during routine toxicological
studies prompted by the advent of large-scale
production of acrylamide monomer for the
polymer industry. That acrylamide is neuro-
toxic to man was discovered in 1954, shortly
after the commencement of manufacture of
acrylamide from acrylonitrile, when several
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factory workers developed peripheral nerve
disease. Since this time, more instances of
human acrylamide intoxication with peripheral
neuropathy have been reported, in individuals
engaged both in the manufacture and in the
use of acrylamide monomer (9-13).
The present concern with the neurotoxic
property of acrylamide monomer is related to
the vast and increasing production of the
chemical for the manufacture of high molecular
polymers which enjoy important applications
in industry and commerce (14). There are two
areas for concern, both of which arise from
the central features of acrylamide neurotoxicity
that the effects of acrylamide are related to
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system damage develops insidiously (2,4,15-
18): one is the degree to which people employed
to manufacture acrylamide are daily exposed to
the neurotoxin, and second, the extent of the
exposure of the populace through the deploy-
ment in the environment of acrylamide poly-
mers contaminated with small amounts of
acrylamide monomer (19).
Human Intoxication
Acrylamide intoxication in industry appears
to result from repetitive daily local dermal
contact (12,20). The small molecular size and
great solubility promote the ready skin absorp-
tion of acrylamide (2). Commonly, contact
with acrylamide is marked by a local dermatitis
(21). Acrylamide intoxication may first become
evident in the form of excessive fatigue, somno-
lence and weight loss (12). Signs of nervous
system damage appear slowly; first in the feet
and hands and later in the legs and arms. In-
dividuals may complain of pins and needles,
numbness, coldness, or excessive sweating (9,
22). Fine movements of the hands, such as
writing and shaving, become noticeably diffi-
cult, and there may be an impairment of tem-
perature sensation. Weakness in the hands and
legs may progress to a frank loss of power
with prominent atrophy of the small muscles
of the hand. These neurologic signs may be
correctly attributed to progressive peripheral
nerve damage which begins in the distal ex-
tremities and proceeds proximally with time
and maintained exposure. If individuals are
removed from contact with acrylamide, the
peripheral neuropathy slowly disappears al-
though animal studies indicate a re-exposure
may precipitate symptoms more readily (3,23).
In addition to signs of peripheral neuropathy,
some affected individuals developed signs of
central nervous system damage such as tremor,
an ataxic gait, or a mild organic mental syn-
drome (9,12,13).
Neuropathology
Peripheral nerve biopsies obtained from
three patients recovering from acrylamide
neuropathy were examined by Fullerton (24).
In one, there was a marked loss of large diam-
eter nerve fibers, a pattern which was repeated
in the nerves of baboons recovering from acryl-
amide neuropathy (25). Systematic study of
the pattern of nerve fiber damage in experi-
mental animals demonstrated that distal re-
gions of nerves were more severely affected
than proximal parts (4). It was possible to
demonstrate in an individual nerve fiber that
distal degeneration coexisted with proximal
preservation (26). After animals had recovered
for several months, the distal parts of affected
fibers had undergone regeneration. These
studies led to the conclusion that in acrylamide
neuropathy nerve fibers undergo a slow, pro-
gressive retrograde degeneration, a pattern
of damage termed "dying-back" (27,28).
Studies ofothertoxic industrial chemicals, for
example the cresyl phosphates and methyl n-
butyl ketone, have shown that, like acrylamide,
these also produce dying-back axonal degenera-
tion (29,30). It has been realized that the
extremities of long and large nerve fibers are
especially vulnerable and that these are the
first to undergo the retrograde changes (25,28).
It has also been demonstrated that in dying-
back diseases the peripheral nervous system is
not exclusively affected and that distal de-
generation also occurs in certain long nerve
fibers tracts of the central nervous system (31).
Thus, in acrylamide-intoxicated cats, axonal
degeneration occurs in the medulla, in the an-
terior and lateral columns of the spinal cord,
and in the nerve terminals of the cerebellum
(27,32,33). The recognition of a central
nervous system component in acrylamide neu-
ropathy was crucial since, unlike the peripheral
nerve degeneration which can recover with
time, central nervous system regeneration is
unlikely to occur.
With the dying-back process in acrylamide
neuropathy firmly established by previous in-
vestigators, we turned our attention to estab-
lishing the peripheral- site at which axonal
degeneration first occurred (28). Cats were
slowly intoxicated with injected acrylamide
and biopsies were repeatedly performed before
and during the illness. Fine nerves, slips of
muscle, and Pacinian corpuscles were sampled
in hindfeet paws. In this way, we were able
to examine the distal tips of some of the longest
nerve fibers in the body; sensory nerves supply-
ing Pacinian corpuscles, which detect touch
and vibratory stimuli, muscle spindle primary
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adjacent motor nerve terminals which trans-
mit impulses for muscular contraction. These
studies revealed that Pacinian corpuscle axons
began to degenerate first, sometimes before
the onset of clinical signs; shortly thereafter,
muscle spindle axon degeneration began and
much later, adjacent motor nerve terminals
started to change. This study demonstrated
that certain sensory nerve terminals were
more vulnerable to acrylamide than adjacent
motor nerve terminals, a finding which seems
to correlate both with clinical evidence of early
sensory deficit and the proportionately greater
and earlier impairment of electrical conduction
in sensory nerve fibers (2,4,5,9,24,25).
Site of Neurotoxic Action
The basis for the neurotoxic property of
acrylamide is unknown. Presumably, the prop-
erty is related to the high reactivity of the
acrylamide molecule which is not significantly
metabolized in vivo (34,35). It has been pro-
posed that acrylamide acts as a nicotinamide
antagonist (17) and it has been demonstrated
that the molecule is able to react with nervous
system proteins (36).
The mechanism by which acrylamide pro-
duces dying-back axonal damage is also un-
known. One explanation is that acrylamide
interferes with the metabolic machinery of
the nerve cell body which gradually fails in its
function to provide material for the axon (37).
This leads to a depletion in the amount of
material reaching the distal regions of axons
where degeneration begins (36,38). Another
hypothesis suggests that acrylamide inactivates
the axonal transport system by which sub-
stances, assembled in the neuron cell body, are
transported along the axon (39,40). Finally,
it has been suggested that if acrylamide inac-
tivated a substance in the axon, which is de-
pendent for its supply on the nerve cell body,
this alone could account for the dying-back
process (7,27,28). These theories have been
discussed in detail elsewhere (33).
Protection of the Factory Worker
Education and hygiene are required to pro-
tect factory workers engaged in the manufac-
ture of acrylamide monomer. It should be ex-
plained that acrylamide is a contact poison,
that the effects are not noticed immediately
because acrylamide damages the nervous svs-
tem only after a prolonged exposure, that the
effects of acrylamide are cumulative, and that
brain and nerve damage are the known results
of exposure. In regard to hygiene, dermal
contact should be prevented by protective
clothing in the form of long polyvinyl gloves,
light washable overalls, a head covering, a face
shield and a mask to prevent inhalation of air-
borne dust. Good washing facilities should be
provided, smoking or eating on the job for-
bidden, and protective clothing changed regu-
larly. Individuals exposed to acrylamide mono-
mer should be encouraged to report any unex-
plained change in health status such as skin
peeling, excessive tiredness, "pins and needles"
sensations, numbness, or sweating in the hands
or feet. Warning labels on bags of monomer
should contain a clear message that acrylamide
is a contact poison and that repetitive exposure
might result in brain and nerve damage.
In addition to education and hygiene, a
simple test is needed to check the health of
workers daily exposed to acrylamide monomer.
Unfortunately, monitoring urine would not
provide information on the amount of protein-
bound acrylamide accumulating in the body
(19). A blood test might be more informative,
since acrylamide is strongly bound to hemo-
globin (18), but such a test would be time-
consuming, expensive, and unlikely to be tol-
erated by factory workers. Clinical measure-
ments of nerve conduction are not reliable indi-
cators of early peripheral nerve disease of the
dying-back type, since the initial changes in
the nerve affect only a few fibers and the
predominant change is at the distal tip.
A promising area which is presently under
consideration springs from the observation
that Pacinian corpuscles are one of the most
vulnerable structures in intoxicated cats (28).
If it is possible to demonstrate that the human
corpuscle is likely to behave in the same way,
it may be feasible to develop a sensitive, prac-
tical and economic test based on periodic
examination of palmar sensibility.
Control Measures
The singular importance of acrylamide to
the polymer industry is evident from the fact
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tion is estimated to be 50 million pounds and
to be increasing rapidly. Perhaps no other
potentially neurotoxic substance is produced
in such vast quantities or enjoys the importance
that acrylamide has assumed in the production
of commercially useful polymers. Because of
the neurotoxic potential of acrylamide, it is
essential that its manufacture and its use
conform to realistic safety standards which
will prevent dangerous exposure either to fac-
tory workers or to the populace.
At the present time, it is recommended that
factory workers should not be daily exposed
to more than 0.5 mg/kg acrylamide monomer
and that air levels should not exceed 0.3 mg/m3
(2,41). Since cases of acrylamide neuropathy
still occur in factory workers, either these
permitted levels are too high, or precautions
taken to reduce exposure to an acceptable level
are inadequate.
The second area for some concern lies in
the present practice permitting some residual
contamination of polymers by the neurotoxic
acrylamide monomer. Up to 2% residual mono-
mer is considered acceptable for some industrial
applications of polyacrylamide, as in the floc-
culation of ore slimes (14). The Food and Drug
Administration has established a maximum
level of 0.05%o residual acrylamide monomer
for polymers used in paper and paperboard in
contact with foodstuffs. Similar levels are con-
sidered satisfactory for the polymers used in
the clarification of potable water and cane-
sugar juice. These levels have been calculated
from data obtained in a clinical study of pri-
mate acrylamide intoxication conducted ten
years ago (2). Because of recent data which
have underlined the danger of prolonged low
level exposure, the possibility of irreversible
central nervous system effects and the identifi-
cation of peripheral nerve damage before clini-
cal symptoms appear, it seems important to
confirm that present regulations are adequate.
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